BioCentury
ARTICLE | Clinical News

PMI-001: Phase IIb data

August 31, 2009 7:00 AM UTC

A completer analysis of 62 patients from a double-blind, active-controlled, U.S. Phase IIb trial showed that 60 mg PMI-001 thrice daily met the primary endpoint of an ACR20 response at 6 months compar...